Universitätsklinikum Schleswig-Holstein (UKSH)

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML (2025) Stasik S, Eckardt JN, Röllig C, Baldus CD, Platzbecker U, Serve H, Müller-Tidow C, et al. Journal article Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status (2025) Placke JM, Rajcsanyi LS, Herbst R, Terheyden P, Utikal J, Pföhler C, Kreuter A, et al. Journal article Preferred Working Time Models and Equal Opportunities in Gynecology and Obstetrics: Results of the Systematic Trinational FARBEN Survey (2025) Tauber N, Amann N, Foessleitner P, Klee A, Becker C, Kiblawi R, Göpfert M, et al. Journal article Implant-based reconstruction and adjuvant radiotherapy in breast cancer patients—current status and DEGRO recommendations (2025) Piroth MD, Krug D, Baumann R, Strnad V, Borm K, Combs S, Corradini S, et al. Journal article Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer (2025) Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, Denkert C, et al. Journal article Best Practice Guidelines-DEGUM Recommendations on Breast Ultrasound: Part III/2 – Special Clinical Indications Best Practice Guideline – Empfehlungen der DEGUM zur Durchführung und Beurteilung der Mammasonografie: Teil III/2 – Spezielle Indikationsbereiche (2025) Vogel-Minea CM, Bader W, Blohmer JU, Duda V, Eichler C, Fallenberg E, Farrokh A, et al. Journal article Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19. (2025) Sähn MJ, Wienke A, Meyer HJ, Dietz J, Vogl TJ, Borggrefe J, Gussew A, et al. Journal article Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study (2025) Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, et al. Journal article Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99, (S0959804922005226), (10.1016/j.ejca.2022.08.029)] (2025) Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, Kähler KC, et al. Journal article, Erratum Automated Multicohort Mobility Assessment with an Instrumented L-test (iL-test) (2025) Albites-Sanabria J, Palumbo P, D'ascanio I, Bonci T, Caruso M, Salis F, Cereatti A, et al. Journal article